Barclays downgraded Novo to ‘Equal Weight’ from ‘Overweight’ with a price target of DKK 375, down from DKK 700.

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk shares dropped as much as 17% Tuesday after the obesity drugmaker cut its full-year sales and profit outlook for ...

Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability ...

U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...

In this week’s edition of InnovationRx, we look at Halle Berry’s menopause startup, Ambience Healthcare’s $243 million ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Today’s Forbes Daily covers Pacific tsunami activity after powerful quake, Trump breaks with Netanyahu over Gaza, the Forbes 50 Over 50, a railroad merger and more.

Novo Nordisk fell by 21.83 percent on Tuesday to end at $53.94 apiece as investors unloaded positions following the company’s ...

Danish leader will face a challenging landscape among competitors ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk's technical chart is displaying a largely bearish trend amid a profit warning tied to its blockbuster obesity ...